Distributed

No. 21-202

Mylan Laboratories Ltd. v. Janssen Pharmaceutica, N.V., et al.

from the United States Court of Appeals for the Federal Circuit

See other cases from the Federal Circuit.

Docket Entries

DISTRIBUTED for Conference of 1/14/2022.

Rescheduled.

Reply of petitioner Mylan Laboratories Ltd. filed. (Distributed)

DISTRIBUTED for Conference of 12/3/2021.

Brief of respondent Janssen Pharmaceutica NV in opposition filed.

Brief of respondent Andrew Hirshfeld in opposition filed.

Motion to extend the time to file a response is granted and the time is further extended to and including November 2, 2021, for all respondents.

Motion to extend the time to file a response from October 12, 2021 to November 2, 2021, submitted to The Clerk.

Brief amicus curiae of Intel Corporation filed.

Brief amicus curiae of Association for Accessible Medicines filed.

Brief amicus curiae of Jeremy C. Doerre in support of neither party filed.

Motion to extend the time to file a response is granted and the time is extended to and including October 12, 2021, for all respondents.

Motion to extend the time to file a response from September 13, 2021 to October 12, 2021, submitted to The Clerk.

Petition for a writ of certiorari filed. (Response due September 13, 2021)

Parties

Mylan Laboratories Ltd., Petitioner, represented by Robert Thomas Smith

Janssen Pharmaceutica NV, Respondent, represented by Pratik Arvind Shah

Amici Curiae

Association for Accessible Medicines, Amicus Curiae, represented by Matthew S. Hellman

Intel Corporation, Amicus Curiae, represented by Donald B. Verrilli Jr.

Jeremy C. Doerre, Amicus Curiae, represented by Jeremy Cooper Doerre

 
Last updated: January 16, 2022